Detalhe da pesquisa
1.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
BMC Cancer
; 23(1): 710, 2023 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516867
2.
Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs.
J Antimicrob Chemother
; 74(6): 1572-1577, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30789224
3.
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
J Clin Oncol
; 41(2): 373-384, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36070539
4.
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.
Front Oncol
; 12: 957580, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35928870
5.
ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
Front Med (Lausanne)
; 8: 713047, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34926483
6.
Efficacy of trabectedin in metastatic solitary fibrous tumor.
Rare Tumors
; 3(3): e29, 2011 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-22066036